Trading Statement January - March 2025   Holzminden, April 29, 2025                                                   Symrise delivers solid growth in Q1 and reaffirms outlook — Achieved organic growth of 4.2% — Delivered sales of €1.3 billion driven primarily by higher volumes — Reaffirms full year 2025 guidance: Organic growth 5-7% / EBITDA  [ … ]

Press Release — Holzminden, March 27, 2025                       Symrise raises dividend and confirms outlook   Dividend proposal of € 1.20 per share (2023: € 1.10) – 15th increase in succession Symrise confirms targets for 2025: Organic growth of 5-7 % Profitability (EBITDA margin) of around 21 % expected Executive Board contract of Dr.  [ … ]

Press Release — Holzminden, 21 February 2025 Symrise accelerates in Human Health and Pet Nutrition through a strategic partnership with HBC This partnership ideally complements Symrise’s current portfolio with clinically proven marine ingredients HBC, a leading manufacturer of human grade, sustainable marine proteins, collagens and oils from Norw [ … ]

 Press release — Holzminden, January 30, 2025 Preliminary financial results 2024              Organic growth of 8.7% / Group sales increase by 5.7% to around €5 billion (2023: €4.7 billion)  EBITDA of €1,033 million significantly above previous year's figure (2023: €903 million1) EBITDA margin rises to 20.7% (2023: 19.1%) Net Income increas [ … ]